Electromed, Inc. (ELMD)
NYSE American · Healthcare · Medical Devices
$28.32+0.78%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $235M
- P/E (trailing)
- 21.8
- Forward P/E
- 46.4
- 52-week range
- $23.01 – $47.40
- 52-week change
- +14.04%
- EPS (trailing)
- $1.30
- Next earnings
- Nov 11, 2026
Fiscal year to Jun 2026
- Revenue
- $73.8M (+15.27%)
- Net income
- $11.3M
- Operating margin
- 18.8%
- Diluted EPS
- $1.30
- Free cash flow
- $8.4M
From the company’s annual report on SEC EDGAR.
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company provides SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting.
Headquarters: New Prague, United States · 195 employees · smartvest.com